Mucopolysaccharidosis Type II Observational
← catalyst calendarSponsored by REGENXBIO Inc. (industry) · RGNX — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Sites
3
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Mar 2022 | estimated | When the study began enrolling |
| Primary completion | Jul 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mucopolysaccharidosis II
Intervention
- Other: Observational
Primary outcomes
what the primary-completion date above is the date OFChanges in neurodevelopmental parameters of cognitive function over time
measured 104 weeks
Changes in neurodevelopmental parameters of cognitive function over time
measured 104 weeks
Changes in neurodevelopmental parameters of adaptive behavior function over time
measured 104 weeks
Permalink · RGNX's whole pipeline · Catalyst calendar · Every registered study · What changed